RIGAKU
9.5.2024 16:01:35 CEST | Business Wire | Press release
Rigaku Corporation, a Rigaku Holdings Group company and Rigaku global solution partner in X-ray analytical equipment (head office: Akishima, Tokyo; president and representative director: Jun Kawakami; hereinafter “Rigaku”), has completed analysis of particles from 101955 Bennu, a near-Earth carbonaceous asteroid classified as a type B. The analysis was performed using ZSX Primus IV, a wavelength dispersive X-ray fluorescence spectrometer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508939191/en/
ZSX Primus IV (Photo: Business Wire)
The particles from Bennu are a sample obtained by OSIRIS-Rex, a spacecraft of the United States National Aeronautics and Space Administration (NASA). This analysis constitutes the second time Rigaku has been tasked with conducting analysis related to Bennu. On the first occasion, in December 2023, Rigaku measured water and carbon content in a sample from the carbonaceous asteroid using thermoanalysis.
The X-ray fluorescence spectrometry was conducted by the Rigaku Application Laboratory XRF Analytical Group in the presence of Professor Hisayoshi Yurimoto of the Faculty of Science, Hokkaido University, who directed the chemical analysis of samples brought back from the asteroid Ryugu by the Hayabusa 2 spacecraft.
The purpose of the analysis was to ascertain the content of major and trace elements including carbon and oxygen in sample. In the current measurements, quantitative analysis was performed on 26 elements Results of thermoanalysis and X-ray spectrometry were combined to learn about the history of Bennu and its similarities and differences with Ryugu.
The analysis of Bennu is now proceeding by worldwide project teams. A unique feature of the work of the Japan team, under the direction of Professor Yurimoto, is the application of thermoanalysis using thermogravimetry along with mass spectrometry and X-ray spectrometry using a wavelength dispersive X-ray fluorescence spectrometer.
One advantage of the Rigaku approach to thermoanalysis is that quantitative-analytical equipment is used in tandem, enabling Rigaku to separate and measure each element and type of molecule, with the result that unprecedented data can be obtained. Moreover, X-ray fluorescence spectrometry plays an exceptionally vital role: As the research method shifts toward inductively coupled plasma mass spectrometry (ICP-MS), X-ray fluorescence spectrometry can analyze major components such as carbon, oxygen, silicon and sulfur that are difficult to analyze using ICP-MS.
Professor Yurimoto commented: “The performance of the equipment is obviously vital, but in the end, what makes the difference is people. When conducting analysis on the leading edge of the field, the question of who does the analysis is paramount. I asked Rigaku to perform the analysis because this company brings to the table not only outstanding equipment but also superb engineers.”
Rigaku will continue to pursue close partnership with academia, contributing to the development of society through the advance of science and technology.
Related information
-
Press release regarding thermoanalysis conducted in December 2023
URL: https://rigaku.com/about/news-and-press-releases/rigaku-analyzes-samples-from-nasa?hsLang=en
Results of Rigaku’s Participation in the Initial Analysis Project of Ryugu Sample
In June 2019, Rigaku took part in the Ryugu project as a joint research partner. In 2021, the content percentages of elements in the sample from Ryugu were determined using ZSX Primus IV, a wavelength dispersive X-ray fluorescence (WDXRF) spectrometer. Measurements using TG-DTA/GC‐MS determined that the moisture content of the sample from Ryugu differed from that found in meteorites of carbonaceous chondrite, which are thought to reflect the mix of elements in the primordial solar system. These data now serve as the basic data from the Ryugu sample that research groups around the world are using to conduct a wide range of analyses.
Rigaku’s analytical results are cited in a paper by the chemical analysis team (led by Prof. Yurimoto) of the initial analysis team of the Hayabusa 2 mission, and are published in Science, a US-based scientific journal.
About The Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including in its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku.com (As of November 30, 2023)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508939191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
